Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | STK4 | Q13043 | 8/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24510016 | 0.85 | LMNA (0.43) | CYP3A4XDHLMNACYP1A2STK4 | |
| SCHEMBL22978512 | 0.85 | KDM4E (0.46) | XDHLMNACYP1A2KCNJ1SMN1; SMN2 | |
| SCHEMBL22978578 | 0.84 | ALDH1A1 (0.43) | FGFR4MAPK8SMN1; SMN2 | |
| SCHEMBL22990240 | 0.82 | ALDH1A1 (0.44) | CYP3A4TSHRXDHLMNACYP1A2 | |
| SCHEMBL22990318 | 0.76 | TSHR (0.46) | CYP3A4TSHRCYP1A2HSD17B10 | |
| SCHEMBL22980867 | 0.76 | CYP3A4 (0.46) | CYP3A4TSHRLMNA | |
| SCHEMBL30525611 | 0.76 | TSHR (0.46) | CYP3A4TSHRCYP1A2HSD17B10 | |
| SCHEMBL22990369 | 0.76 | STK4 (0.43) | CYP3A4XDHLMNACYP1A2STK4 | |
| SCHEMBL22978661 | 0.76 | CYP3A4 (0.42) | CYP3A4TSHRXDHLMNACYP1A2 | |
| SCHEMBL24135448 | 0.76 | S1PR2 (0.42) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| CN-116783188-A | Dihydro-isoquinolone derivative and application thereof | 上海奕拓医药科技有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| EP-4010334-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | Novartis AG (CH) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028806-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021026672-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021026672-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | WDR5, WDR1, WDR77 | CYP3A4 2772/4885TSHR 4810/4885XDH 2683/4885 |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | CYP3A4 4769/4885TSHR 4836/4885XDH 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.